Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004211 · Duke University, Other · Completed
Key facts
| NCT number | NCT00004211 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer |
| Official title | A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With RNA Encoding Prostate Specific Antigen, PSA |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | PSA RNA-pulsed dendritic cell vaccine |
| Enrollment | 17 |
| Start date | Jul 1, 1999 |
| Completion | Jan 1, 2002 |
| First posted | May 20, 2004 |
| Last update posted | Mar 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: